This presentation and other written or oral statements made from time to time by representatives of Niagen Bioscience contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements reflect the current view about future events. Statements that are not historical in nature, such as 2025 financial outlook, and which may be identified by the use of words like "expects ...

Q3 2025 Financial Highlights November 4, 2025 PAGE 2 Note on Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of U.S. federal securities laws. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would," or similar expres ...

Third Quarter 2025 Financial Results Conference Call November 4, 2025 Matt, an XDEMVY® Patient Today's Speakers Bobby Azamian, MD, PhD CEO & Chairman Aziz Mottiwala Chief Commercial Officer Jeff Farrow Chief Financial & Strategy Officer 2 | © Tarsus Pharmaceuticals | For Investor Purposes Only Forward-Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. These statements and the most recent Form 10-Q quarterly filing filed with the SEC include stateme ...

Financial Performance - Q3 production reached 213800 Boe/d, with over 53% being oil[15] - Adjusted EBITDAX for Q3 was $5882 million[15] - Adjusted Free Cash Flow for Q3 was $2343 million[15] - Net debt reduced by over $60 million, resulting in a leverage of 11x[15] Capital Allocation - Share repurchases in Q3 amounted to $12 million[15] - A cash dividend of $020 per share was paid in Q3, resulting in an annualized dividend yield of 4%[15] - Cumulative capital returned to stockholders reached $625 million, with over 35% of FCF returned[24] Operational Highlights - Estimated Net Proved Reserves increased by 68% from December 31, 2020, to December 31, 2024[10] - Total Net Production is expected to increase by 64% from full-year 2020 to estimated full-year 2025[10] - Oil Production is expected to increase by 76% from full-year 2020 to estimated full-year 2025[10]

Mirum Pharmaceuticals: Transforming Lives in Rare Disease N o v e m b e r 2 0 2 5 Forward-Looking Statements This presentation contains "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our business strategy, objectives and opportunities, including the future oppo ...

Disclaimer and Forward-Looking Statements This presentation contains "forward-looking" statements, as defined under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on our management's beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical facts contained in this presentation, including statements regarding our d ...

Corporate Presentation November 4, 2025 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements related to the potential benefits of Vaxcyte's carrier-sparing platform and vaccine candidates, including breadth of coverage and the ability to deliver potentially better immune responses, a potentially best-in-class pneumococcal conjugate vaccine (PCV) ...

This presentation may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking s ...

Corvus Corporate Presentation November 2025 ITK Inhibitor Platform Opportunity Novel MOA with broad opportunities in oncology and immune diseases The Power to Control Immunity Forward-Looking Statements / Safe Harbor This presentation and the accompanying oral presentation contain "forward‐looking" statements related to the potential of the Company's product candidates including soquelitinib and the interim results from the Phase 1 trial of soquelitinib in patients with atopic dermatitis, the design and tim ...

PTC Therapeutics November 2025 Pam and Kelsey living with PKU This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historic fact, are forward-looking statements, including statements regarding: the future expectations, plans and prospects for PTC, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory subm ...